癌症患者抗凝治疗期间复发性静脉血栓栓塞的治疗与结局:Hokusai静脉血栓栓塞癌症研究的事后分析
该事后分析纳入Hokusai VTE癌症试验中12个月内发生经裁定的抗凝治疗期间复发性VTE的患者,描述复发后抗凝策略及3个月内第二次复发和大出血结局。共67例患者发生治疗期间复发性VTE,复发后抗凝策略异质,3个月内6例(9%)第二次复发、7例(10%)大出血。作者认为需更多研究确定最佳治疗策略。
要点
- 癌症患者抗凝治疗期间复发性VTE后抗凝策略异质,常见为治疗剂量低分子肝素(51%)。
- 复发性VTE后3个月内第二次复发6例(9%),大出血7例(10%)。
- 作者认为需更多研究确定复发性癌症相关血栓的最佳治疗策略。
核心结论
- 癌症患者抗凝治疗期间复发性VTE的治疗策略异质,第二次复发和大出血风险均相当可观,需更多研究确定最佳治疗策略。
研究设计与样本
- Hokusai VTE癌症试验的事后分析,纳入随机化后12个月内经裁定的抗凝治疗期间复发性VTE的全部患者。
- Hokusai VTE癌症试验比较艾多沙班与达肝素治疗癌症相关VTE。
主要发现
- 共67例患者发生抗凝治疗期间复发性VTE,当时接受治疗剂量艾多沙班者占31%、治疗剂量低分子肝素(LMWH)者占34%、维持剂量LMWH者占21%、其他治疗者占14%。
- 复发性VTE后,28例(42%)增加剂量,35例(52%)剂量相当,4例(6%)减少剂量或停止抗凝。
- 常见治疗方案包括超治疗剂量LMWH(21%)、治疗剂量LMWH(51%)、直接口服抗凝药(16%)或其他治疗策略(12%)。
- 复发性VTE后3个月内,6例(9%)发生第二次复发,7例(10%)发生大出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of recurrent venous thromboembolism (VTE) despite anticoagulant treatment in patients with cancer is uncertain. To address this, we used data from the Hokusai VTE Cancer trial, which compared edoxaban with dalteparin to treat cancer-associated VTE. OBJECTIVES: To characterize and evaluate anticoagulant treatment strategies during and after on-treatment recurrent VTE, including the type and dose of anticoagulant. METHODS: In this post hoc analysis, all patients with adjudicated on-treatment recurrent VTE within 12 months after randomization were included. Outcomes were second recurrent VTE and major bleeding within 3 months after the first recurrent VTE. RESULTS: A total of 67 patients developed on-treatment recurrent VTE while receiving therapeutic-dose edoxaban (31%), therapeutic-dose low-molecular-weight heparin (LMWH) (34%), maintenance-dose LMWH (21%), or other therapies (14%). After the recurrent event, 28 patients (42%) received an increased dose, 35 (52%) a comparable dose, and 4 (6%) a reduced dose or stopped anticoagulants. Common treatment regimens included supratherapeutic-dose LMWH (21%), therapeutic-dose LMWH (51%), direct oral anticoagulants (16%), or another treatment strategy (12%). In the 3 months after recurrent VTE, 6 (9%) patients had a second recurrence and 7 (10%) had major bleeding. CONCLUSION: Treatment strategies for recurrent VTE in patients with cancer are heterogeneous. The risk of a second recurrence and major bleeding are considerable. More studies are needed to determine the optimal treatment strategy for recurrent cancer-associated thrombosis.
引用
- Lanting VR, van Bergen En Henegouwen K, Bosch FTM, et al. Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study. J Thromb Haemost. 2025. PMID: 40049418. doi:10.1016/j.jtha.2025.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。